Similarly, prostate cancer diagnosed by prostate-specific antigen (PSA) screening is projected to be the top burden in male cancer incidence in 2020–2054, accounting for one-fifth of new cases among men (Supplementary Table S4). Here, KLK3 is linked to prostate cancer.